Gambaran Umum
Abivax S.A. is a biotechnology company based in Paris, France, that operates within the healthcare sector. The company primarily focuses on the discovery and development of drugs to treat diseases with a high unmet medical need. Among its key projects, Abivax is developing ABX464, its lead candidate for the treatment of moderate to severe ulcerative colitis, Crohn's disease, and rheumatoid arthritis.
Skor Kualitas, Nilai, dan Momentum
Kartu ini menunjukkan skor Kualitas, Nilai, dan Momentum untuk perusahaan tersebut.
Laporan Laba Rugi: Pendapatan, Laba Operasional, Laba Bersih
- Nilai revenue untuk ABIVAX Société Anonyme - Depositary Receipt (Common Stock) per 2025 Mar 31 adalah 10.59 MM.
- Nilai operating income untuk ABIVAX Société Anonyme - Depositary Receipt (Common Stock) per 2025 Mar 31 adalah -175.51 MM.
- Nilai net income untuk ABIVAX Société Anonyme - Depositary Receipt (Common Stock) per 2025 Mar 31 adalah -185.75 MM.
Period End (TTM) | Revenue (MM) | Operating Income (MM) | Net Income (MM) |
2025-03-31 | 10.59 | -175.51 | -185.75 |
2024-12-31 | 10.79 | -172.98 | -176.24 |
2024-09-30 | 9.95 | -171.54 | -176.83 |
2024-06-30 | 9.03 | -170.17 | -177.43 |
2024-03-31 | 4.62 | -153.41 | -164.63 |
2023-12-31 | 4.57 | -127.38 | -147.74 |
2023-09-30 | 4.56 | -100.39 | -119.62 |
2023-06-30 | 4.50 | -73.47 | -91.51 |
2023-03-31 | 4.49 | -62.35 | -76.12 |
2022-12-31 | 4.50 | -51.20 | -60.74 |
2022-09-30 | 7.55 | -44.44 | -53.92 |
2022-06-30 | 2.23 | -37.65 | -47.10 |
2022-03-31 | 1.11 | -43.38 | -44.78 |
2021-12-31 | 4.20 | -49.12 | -42.45 |
2021-09-30 | 0.01 | -49.51 | -40.56 |
2021-06-30 | 0.01 | -49.91 | -38.66 |
2021-03-31 | 0.01 | -44.75 | -38.11 |
2020-12-31 | 0.01 | -39.60 | -37.55 |
2020-09-30 | -0.02 | -35.94 | -34.72 |
2020-03-31 |
Laporan Laba Rugi: EPS
Period End (TTM) | Earnings Per Share Basic | Earnings Per Share Diluted |
2025-03-31 | ||
2024-12-31 | ||
2024-09-30 | ||
2024-06-30 | -3.14 | -3.14 |
2024-03-31 | -3.26 | -3.26 |
2023-12-31 | -3.43 | |
2023-09-30 | -3.34 | -3.34 |
2023-06-30 | -3.19 | -3.19 |
2023-03-31 | -3.19 | -3.19 |
2022-12-31 | -3.18 | |
2022-09-30 | -2.42 | -2.42 |
2022-06-30 | ||
2022-03-31 | -2.67 | -2.67 |
2021-12-31 | -2.75 | |
2021-09-30 | -2.42 | -2.42 |
2021-06-30 | ||
2021-03-31 | ||
2020-12-31 | -2.62 | |
2020-09-30 | -2.43 | -2.43 |
2020-03-31 | -2.56 | -2.56 |
Arus Kas: Operasi, Investasi, Pendanaan
- Nilai cash from operating activities untuk ABIVAX Société Anonyme - Depositary Receipt (Common Stock) per 2025 Mar 31 adalah -152.60 MM.
- Nilai cash from investing activities untuk ABIVAX Société Anonyme - Depositary Receipt (Common Stock) per 2025 Mar 31 adalah 14.94 MM.
- Nilai kas dari aktivitas pendanaan untuk ABIVAX Société Anonyme - Depositary Receipt (Common Stock) per 2025 Mar 31 adalah -0.83 MM.
Period End (TTM) | Cash From Operating Activities (MM) | Cash From Investing Activities (MM) | Cash From Financing Activities (MM) |
2025-03-31 | -152.60 | 14.94 | -0.83 |
2024-12-31 | -154.07 | 15.76 | 28.21 |
2024-09-30 | -154.39 | 11.42 | 143.54 |
2024-06-30 | -154.71 | 7.08 | 258.87 |
2024-03-31 | -118.08 | -5.34 | 298.12 |
2023-12-31 | -97.13 | -8.10 | 335.29 |
2023-09-30 | -76.98 | -9.44 | 245.34 |
2023-06-30 | -56.82 | -10.79 | 155.38 |
2023-03-31 | -55.38 | -11.41 | 93.80 |
2022-12-31 | -53.94 | -12.03 | 32.21 |
2022-09-30 | |||
2022-06-30 | -46.00 | -9.15 | 77.41 |
2022-03-31 | -45.52 | -7.69 | 80.05 |
2021-12-31 | -45.05 | -6.23 | 82.68 |
2021-09-30 | |||
2021-06-30 | -45.24 | -1.10 | 38.63 |
2021-03-31 | -37.53 | -0.84 | 44.28 |
2020-12-31 | -29.82 | -0.57 | 49.93 |
2020-09-30 | |||
2020-03-31 |
Metrik Penilaian: PE, PriceToBook, PriceToTBV
- P/Book
- The current closing price divided by the book value per share.
- P/TBV
- The current price divided by the tangible book value per share.
Period End (TTM) | p/e | P/Book | P/TBV |
2025-03-31 | |||
2024-12-31 | |||
2024-09-30 | |||
2024-06-30 | |||
2024-03-31 | |||
2023-12-31 | |||
2023-09-30 | |||
2023-06-30 | |||
2023-03-31 | |||
2022-12-31 | |||
2022-09-30 | |||
2022-06-30 | |||
2022-03-31 | |||
2021-12-31 | |||
2021-09-30 | |||
2021-06-30 | |||
2021-03-31 | |||
2020-12-31 | |||
2020-09-30 | |||
2020-03-31 |
Metrik Penilaian: EBitToEv, EBit3YrAvgToEv
Period End (TTM) | EBIT/EV | EBIT (3y)/EV |
2025-03-31 | ||
2024-12-31 | ||
2024-09-30 | ||
2024-06-30 | ||
2024-03-31 | ||
2023-12-31 | ||
2023-09-30 | ||
2023-06-30 | ||
2023-03-31 | ||
2022-12-31 | ||
2022-09-30 | ||
2022-06-30 | ||
2022-03-31 | ||
2021-12-31 | ||
2021-09-30 | ||
2021-06-30 | ||
2021-03-31 | ||
2020-12-31 | ||
2020-09-30 | ||
2020-03-31 |
Efektivitas Manajemen
- roa untuk ABIVAX Société Anonyme - Depositary Receipt (Common Stock) pada 2025 Mar 31 adalah -0.62.
- roe untuk ABIVAX Société Anonyme - Depositary Receipt (Common Stock) pada 2025 Mar 31 adalah -0.95.
- roic untuk ABIVAX Société Anonyme - Depositary Receipt (Common Stock) pada 2025 Mar 31 adalah -1.18.
- croic untuk ABIVAX Société Anonyme - Depositary Receipt (Common Stock) pada 2025 Mar 31 adalah -0.72.
- ocroic untuk ABIVAX Société Anonyme - Depositary Receipt (Common Stock) pada 2025 Mar 31 adalah -1.03.
Period End (TTM) | ROA | ROE | ROIC (Tingkat Pengembalian Investasi Modal) | CROIC | OCROIC |
2025-03-31 | -0.62 | -0.95 | -1.18 | -0.72 | -1.03 |
2024-12-31 | -0.54 | -0.90 | -0.74 | 0.45 | -0.65 |
2024-09-30 | -0.54 | -2.20 | -0.74 | 0.45 | -0.65 |
2024-06-30 | -0.86 | -2.05 | -0.54 | 0.83 | -0.36 |
2024-03-31 | -1.21 | -20.50 | |||
2023-12-31 | -1.64 | -20.34 | -1.01 | 1.28 | -0.63 |
2023-09-30 | -1.28 | -15.05 | -0.75 | 0.72 | -0.47 |
2023-06-30 | -1.28 | -15.05 | -0.75 | 0.72 | -0.47 |
2023-03-31 | -1.06 | -2.14 | -0.62 | 0.22 | -0.45 |
2022-12-31 | -0.56 | -26.15 | -1.12 | 0.40 | -0.86 |
2022-09-30 | -0.56 | -26.15 | -1.12 | 0.40 | -0.86 |
2022-06-30 | -0.99 | -22.94 | -0.99 | 0.40 | -0.86 |
2022-03-31 | -0.87 | -2.68 | -0.57 | 0.32 | -0.55 |
2021-12-31 | -0.58 | -2.31 | -0.46 | 0.35 | -0.51 |
2021-09-30 | -0.56 | -2.24 | -0.71 | -0.14 | -0.81 |
2021-06-30 | -0.78 | -4.02 | -1.13 | -0.23 | -1.32 |
2021-03-31 | -0.76 | -3.97 | -0.77 | 0.12 | -0.76 |
2020-12-31 | -0.73 | -2.02 | -0.72 | 0.38 | -0.57 |
2020-09-30 | -0.67 | -1.66 | -0.67 | 0.19 | -0.52 |
2020-03-31 | -0.57 | -0.90 | -0.92 | -0.04 | -0.76 |
Gross Margins
- marjin kotor untuk ABIVAX Société Anonyme - Depositary Receipt (Common Stock) pada 2025 Mar 31 adalah 1.00.
- marjin bersih untuk ABIVAX Société Anonyme - Depositary Receipt (Common Stock) pada 2025 Mar 31 adalah -14.10.
- marjin operasi untuk ABIVAX Société Anonyme - Depositary Receipt (Common Stock) pada 2025 Mar 31 adalah -13.83.
- Margin Kotor
- The Gross Margin is the ratio of revenue left after substracting the Cost of Goods Sold. It is calculated as 1.0 - (Revenue - COGS ) / Revenue.
- Margin Keuntungan Bersih
- Margin Bersih (juga dikenal sebagai Margin Keuntungan) adalah rasio pendapatan yang tersisa setelah dikurangi Pendapatan Bersih. Perhitungannya adalah Pendapatan Bersih / Pendapatan.
- Margin Operasi
- Margin Operasi adalah rasio pendapatan yang tersisa setelah dikurangi Pendapatan Operasi. Perhitungannya adalah Pendapatan Operasi / Pendapatan.
Period End (TTM) | Margin Kotor | Margin Keuntungan Bersih | Margin Operasi |
2025-03-31 | 1.00 | -14.10 | -13.83 |
2024-12-31 | 1.00 | -19.65 | -18.84 |
2024-09-30 | 1.00 | -19.65 | -18.84 |
2024-06-30 | -0.72 | -32.04 | -27.70 |
2024-03-31 | 1.00 | -4,575.50 | -3,673.35 |
2023-12-31 | -5.62 | -103.38 | -85.47 |
2023-09-30 | 1.00 | -4,575.50 | -3,673.35 |
2023-06-30 | 1.00 | -4,575.50 | -3,673.35 |
2023-03-31 | -1,929.95 | -7,612.50 | -6,235.00 |
2022-12-31 | -385.19 | -1,241.79 | -1,008.90 |
2022-09-30 | -385.19 | -1,241.79 | -1,008.90 |
2022-06-30 | 5.79 | 5.73 | 5.66 |
2022-03-31 | 10.58 | 10.09 | 11.15 |
2021-12-31 | -3.69 | -4.27 | -4.38 |
2021-09-30 | -3.44 | -8.20 | -9.46 |
2021-06-30 | -3.21 | -4.82 | -5.23 |
2021-03-31 | -7.40 | -9.47 | -10.14 |
2020-12-31 | -18.87 | -22.12 | -22.29 |
2020-09-30 | 853.21 | 977.96 | 1,012.90 |
2020-03-31 | 6,865.00 | 7,814.75 | 8,196.75 |
Pengenal dan Deskriptor
Kunci Indeks Pusat (CIK) |
Grupong Pang-industriya
SIC 2836 - Biological Products, Except Diagnostic Substances (Biotech) |